Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Better Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates Obtained FDA Authorization for AspyreRxTM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12.5 million in net proceeds Company to host conference call and webcast today at 4:30pm ET"
07/26/2023 8-K Quarterly results
07/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Better Therapeutics Receives FDA Authorization for AspyreRxTM to Treat Adults with Type 2 Diabetes First prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c Company to host conference call and webcast on July 11 at 8:30 a.m. ET"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Opinion of Goodwin Procter LLP",
"ATM Sales Agreement, by and between Better Therapeutics, Inc., and Virtu Americas LLC"
05/11/2023 8-K Quarterly results
Docs: "Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates On track for an FDA decision mid-year Announced restructuring to extend cash runway Completed private placement financing Company to host conference call and webcast today at 8:30 a.m. ET"
04/24/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/02/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer"
09/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Better Therapeutics Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes"
08/11/2022 8-K Quarterly results
07/28/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
03/28/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results"
03/15/2022 8-K Quarterly results
11/22/2021 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
11/18/2021 8-K Investor presentation
Docs: "Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes",
"Company Presentation dated November 2021"
11/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Better Therapeutics Appoints Major General Elder Granger, M.D., U.S. Army to its Board of Directors"
11/03/2021 8-K Director compensation was amended/approved
Docs: "Second Amended and Restated Certificate of Incorporation of Better Therapeutics, Inc., filed October 28, 2021",
"Amended and Restated Bylaws of Better Therapeutics, Inc., effective October 28, 2021",
"BETTER THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Better Therapeutics, Inc. 2021 Employee Stock Purchase Plan is to provide eligible employees of Better Therapeutics, Inc. and each Designated Company with opportunities to purchase shares of the Company's common stock, par value $0.0001 per share . 280,000 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2022 and each January 1 thereafter until the Plan terminates pursuant to Section 20, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the lesser of 560,000 shares of Common Stock, one percent of the number of shares of Common Stock issued and outstanding on the immediately precedi...",
"BETTER THERAPEUTICS, INC. 2021stOCK OPTION AND INCENTIVE PLAN, AS AMENDED SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Better Therapeutics, Inc. 2021stock Option and Incentive Plan . The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Better Therapeutics, Inc. and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company's welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company's behalf an...",
"BETTER THERAPEUTICS, INC. 2020 STOCK OPTION AND GRANT PLAN",
"BETTER THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN",
"BETTER THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Better Therapeutics, Inc., a Delaware corporation , is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries . This Policy will become effective as of the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of April 6, 2021, by and among the Company, MCAD Merger Sub, Inc. and Better Therapeutics OpCo, Inc. . In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below: I. Cash Retaine...",
"BETTER THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT",
"BETTER THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT",
"BETTER THERAPEUTICS, INC. October 28, 2021 David Perry E-mail"
10/27/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "Mountain Crest Acquisition Corp. II Stockholders Approve Business Combination with Better Therapeutics Inc. Trading Under New Ticker Symbol “BTTX” Expected to Begin Friday, October 29, 2021"
09/28/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER THIS SECOND AMENDMENT TO AGREEMENT AND PLAN OF MERGER is made and entered into as of September 27, 2021 by and among Mountain Crest Acquisition Corp. II, a Delaware corporation , MCAD Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent , and Better Therapeutics, Inc., a Delaware corporation . Parent, Merger Sub and the Company are sometimes referred to herein as a “Party” or collectively as the “Parties”. Capitalized terms used and not defined herein have the respective meanings ascribed to them in the Merger Agreement . RECITALS"
09/01/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment to Agreement and Plan of Merger"
08/24/2021 8-K Other Events  Interactive Data
06/04/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Opening Bell Remarks"
05/28/2021 8-K Quarterly results
04/07/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Agreement and Plan of Merger, by and among Mountain Crest Acquisition Corp. II, MCAD Merger Sub Inc. and Better Therapeutics, Inc",
"Parent Support Agreement, by and among Mountain Crest Acquisition Corp. II and founding stockholders of Mountain Crest Acquisition Corp. II",
"Company Support Agreement, by and among Better Therapeutics, Inc. and certain stockholders of Better Therapeutics, Inc",
"Form of Subscription Agreement",
"Form of Lock-Up Agreement",
"Form of Amended & Restated Registration Rights Agreement",
"Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquisition Corp. II",
"Investor Presentation, dated March 2021",
"Transcript of Pre-Recorded Management Presentation"
01/19/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy